Human papillomavirus vaccine - Virometix
Latest Information Update: 28 Dec 2022
Price :
$50 *
At a glance
- Originator Virometix
- Developer GeoVax Labs; German Cancer Research Center; Virometix
- Class Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Human papillomavirus infections
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Human-papillomavirus-infections(Combination therapy) in Switzerland
- 28 Aug 2020 No recent reports of development identified for preclinical development in Human-papillomavirus-infections in Switzerland
- 13 Nov 2018 GeoVax Labs enters a collaboration with Virometix for development of a therapeutic vaccine for human papillomavirus (HPV) infection and related cancers